Gerresheimer said late last month that it tapped Dr. Bernd Metzner as its new chief financial officer, set to take position at the latest by July 1 next year. Prior to joining the Dusseldorf-based company, Metzner acted as CFO at Ströer, a position he took up in June 2014. He also held positions at Bayer […]
Organovo CEO Murphy steps away, Crouch steps up | Personnel Moves | April 14, 2017
Organovo (PINK:ONVO) said earlier this week that Taylor Crouch has been appointed as CEO, replacing Keith Murphy who is stepping away from the company. The changes are slated to go into effect on April 21. Prior to being tapped for the corner office, Crouch operated as CEO of investigative clinical research company eStudySite, the San Diego, […]
Organovo unveils bioprinted liver transplant patches
Organovo (PINK:ONVO) today announced it is developing 3D bioprinted human liver tissue designed for direct transplantation to patients. The move to human development comes based on “strong results” from preclinical animal model studies, the San Diego, Calif.-based company said. The company expects to pursue a formal preclinical development program. “We’re excited to introduce an implantable bioprinted liver […]
Organovo launches bio-printed kidney tissue service
Organovo (PINK:ONVO), the contract research organization known for their 3D bio-printed liver tissue, announced today that it began commercial contracting for its second tissue service, the ExVive Human Kidney. The San Diego, Calif.-based group is widely recognized for their bio-printed liver tissue that pharma giants like Merck and Roche use to assess toxicity for pre-clinical […]
Organovo prices $40m follow-on offering
Organovo (PINK:ONVO) said last week that it priced a $40 million follow-on offering of 9.4 million shares at $4.25 per share. Proceeds are slated for general corporate purposes, the San Diego, Calif.-based company said, including R&D, commercialization of products and other general expenses. Jefferies LLC and Piper Jaffray & Co. are book-runners for the offering, with […]
OvaScience shares up on 1st birth after its fertility treatment
(Reuters) — Shares in OvaScience (NSDQ:OVAS) were up 8% at 1 point today after the company announced the 1st birth of baby resulting from its experimental Augment fertility treatment.
Organovo inks L’Oreal deal for 3d-printed skin
Cali biotech promises a 3D-printed organ this year | MassDevice.com On Call
MASSDEVICE ON CALL — California biotech startup Organovo has its sights set high, promising to demonstrate the promise of 3D bio-printing technology by unveiling a human organ made of printed living cells by the end the year.
Organovo plans to begin organ-printing with the human liver, constructed by laying down layer after layer of human tissue to form a single organ. To do so, the company needs to develop a sort of vascular system to keep the organ fed with nutrients and oxygen, lest it wither on the printer.
The 3D medical printing revolution | MassDevice.com On Call
MASSDEVICE ON CALL — New 3D printing technology has captured imaginations from NASA labs to art studios, but so-called "bio-printing" may be the revolution with the greatest direct human impact.
Boston Scientific hits a new high | Wall Street Beat
Medtech titan Boston Scientific (NYSE:BSX) started the month strong, hitting a new 52-week Wall Street high of $7.86 on Monday, April 1, and topping that with a new high of $7.95 a day later.
Ocular Therapeutix eyes a $24M Series D extension | Wall Street Beat
Ocular Therapeutix said it closed a $23.8 million Series D extension round from existing backers for its sustained drug release technology to treat eye diseases.
The Bedford, Mass.-based medical device company said all of its current institutional investors ponied up for the round, including Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta LLC, and Ascension Health Ventures.
Ocular Therapeutix is developing a punctum plug for the entry of the tear duct to release drug therapy to the surface of the eye over several months.
